Graticule Asia Macro Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Graticule Asia Macro Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-25,000	Closed	-$1.4M	–	140
2017 Q2	$1.4M	Buy	+25,000	New	+$1M	0.07%	97
2016 Q2	–	Sell	-10,118	Closed	-$206K	–	101
2016 Q1	$206K	Buy	10,118 +935	+10%	+$29.7K	0.02%	80
2015 Q4	$474K	Buy	+9,183	New	+$445K	0.08%	158

Other funds holding PTLA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Graticule Asia Macro Advisors's PTLA Position: Q3 2017 in Review

Graticule Asia Macro Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2017, closing a stake of 25,000 shares — an estimated $1.4M sold.

Graticule Asia Macro Advisors first reported a position in PTLA in Q4 2015 and held it in 3 quarters. The position peaked at $1.4M in Q2 2017. 221 funds tracked by Wall St. Rank hold PTLA as of Q3 2017.

Graticule Asia Macro Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Graticule Asia Macro Advisors sold 25,000 Portola Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.4M.
Graticule Asia Macro Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 3 quarters.
Graticule Asia Macro Advisors's Portola Pharmaceuticals, Inc. position peaked at $1.4M in Q2 2017.
221 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2017.

Based on Graticule Asia Macro Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.